HIF inhibition in metastatic renal cell carcinoma (RCC): FINAL results from a phase 1-2a clinical trial evaluating the nanoparticle-drug conjugate, CRLX101, in combination with bevacizumab
Publication
, Conference
Keefe, SM; Hoffman-Censits, J; Cohen, RB; Eliasof, S; Garmey, EG; Gunnarsson, O; Hennessy, M; Jayaraman, L; Mamtani, R; Mannan, AM; Nixon, AB ...
Published in: BJU INTERNATIONAL
2015
Duke Scholars
Published In
BJU INTERNATIONAL
EISSN
1464-410X
ISSN
1464-4096
Publication Date
2015
Volume
116
Start / End Page
10 / 11
Related Subject Headings
- Urology & Nephrology
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Keefe, S. M., Hoffman-Censits, J., Cohen, R. B., Eliasof, S., Garmey, E. G., Gunnarsson, O., … Haas, N. B. (2015). HIF inhibition in metastatic renal cell carcinoma (RCC): FINAL results from a phase 1-2a clinical trial evaluating the nanoparticle-drug conjugate, CRLX101, in combination with bevacizumab. In BJU INTERNATIONAL (Vol. 116, pp. 10–11).
Keefe, Stephen M., Jean Hoffman-Censits, Roger B. Cohen, Scott Eliasof, Edward G. Garmey, Orvar Gunnarsson, Meliessa Hennessy, et al. “HIF inhibition in metastatic renal cell carcinoma (RCC): FINAL results from a phase 1-2a clinical trial evaluating the nanoparticle-drug conjugate, CRLX101, in combination with bevacizumab.” In BJU INTERNATIONAL, 116:10–11, 2015.
Keefe SM, Hoffman-Censits J, Cohen RB, Eliasof S, Garmey EG, Gunnarsson O, et al. HIF inhibition in metastatic renal cell carcinoma (RCC): FINAL results from a phase 1-2a clinical trial evaluating the nanoparticle-drug conjugate, CRLX101, in combination with bevacizumab. In: BJU INTERNATIONAL. 2015. p. 10–1.
Keefe, Stephen M., et al. “HIF inhibition in metastatic renal cell carcinoma (RCC): FINAL results from a phase 1-2a clinical trial evaluating the nanoparticle-drug conjugate, CRLX101, in combination with bevacizumab.” BJU INTERNATIONAL, vol. 116, 2015, pp. 10–11.
Keefe SM, Hoffman-Censits J, Cohen RB, Eliasof S, Garmey EG, Gunnarsson O, Hennessy M, Jayaraman L, Mamtani R, Mannan AM, Nixon AB, Piscitelli A, Robinson J, Smith A, Tellez AB, Vaughn D, Walicki M, Haas NB. HIF inhibition in metastatic renal cell carcinoma (RCC): FINAL results from a phase 1-2a clinical trial evaluating the nanoparticle-drug conjugate, CRLX101, in combination with bevacizumab. BJU INTERNATIONAL. 2015. p. 10–11.
Published In
BJU INTERNATIONAL
EISSN
1464-410X
ISSN
1464-4096
Publication Date
2015
Volume
116
Start / End Page
10 / 11
Related Subject Headings
- Urology & Nephrology
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1103 Clinical Sciences